Condition: Adynamic Bone Disease · Chronic Kidney Diseases · Cardiac Disease · Sponsor: Ditte Hansen
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for treatment of adynamic bone disorder in patients with chronic kidney disease.
This description comes directly from the study's public registry record.
Sabina C Hauge, MD · +4528965887 · sabina.chaudhary.hauge@regionh.dk
Ditte Hansen, MD, PhD · +4538682056 · ditte.hansen.04@regionh.dk
Always discuss trial participation with your own doctor first.
| Aalborg University Hospital | Aalborg, Denmark | Not Yet Recruiting |
| Steno Diabetes Center Copenhagen | Gentofte Municipality, Denmark | Not Yet Recruiting |
| Herlev and Gentofte Hospital, Herlev Hospital | Herlev, Denmark | Recruiting |
| Odense University Hospital | Odense, Denmark | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04522622